Back to All Combinations
KRAS + APC
Intermediate PrognosisGenes Involved
KRAS
APC
Recommended Treatments
Standard chemotherapy
Bevacizumab-based
Treatments to Avoid
Anti-EGFR monotherapy
Key Statistics
30.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Very common combination. APC loss is an early event in most CRCs.
Information
Category: General
Evidence Level: B
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.